Login to Your Account



Clinic Roundup


Friday, February 10, 2012
• Moberg Derma AB, of Stockholm, Sweden, said its Phase II trial of MOB-015, a topical drug for nail fungus, is unlikely to produce results sufficient for out-licensing, and additional studies likely will be needed before Phase III. The assessment was based on an interim analysis; full data are expected by the end of the year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription